Community interventions and the epidemic prevention potential

Vaccine

Volumn 20, Issue 27-28, 2002, Pages 3254-3262

  Elizabeth Halloran, M ^a   Longini, Ira M ^a   Cowart, David M ^a   Nizam, Azhar ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Community trials; Efficacy; Influenza; Vaccines

Indexed keywords

INFLUENZA VACCINE;

COMMUNITY CARE; DISEASE TRANSMISSION; EPIDEMIC; HUMAN; INFLUENZA; INFLUENZA VACCINATION; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; REVIEW; STOCHASTIC MODEL; THERAPY;

EID: 0037056035     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00316-X     Document Type: Article

References (39)

1. Struchiner C.J., Halloran M.E., Robins J.M., Spielman A., The behavior of common measures of association used to assess a vaccination program under complex disease transmission patterns - a computer simulation study of malaria vaccines. Int J Epidemiol. 19:1990;187-196.
2. Halloran M.E., Struchiner C.J., Study designs for dependent happenings. Epidemiology. 2:1991;331-338.
3. Halloran M.E., Struchiner C.J., Longini I.M., Study designs for different efficacy and effectiveness aspects of vaccination. Am J Epidemiol. 146:1997;789-803.
4. Clemens J., Brenner R., Rao M., Tafari N., Lowe C., Evaluating new vaccines for developing countries: efficacy or effectiveness? J Am Med Assoc. 275:1996;390-397.
5. Moulton L.H., O'Brien K.L., Kohberger R., Chang I., Reid R., Weatherholtz R., et al. Design of a group-randomised Streptococcus pneumoniae vaccine trial. Control Clin Trials. 22:2001;438-452.
6. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted disease on HIV infection in rural Tanzania: Randomised controlled trial. Lancet 1995;346:530-6.
7. Hayes R, Mosha F, Nicoll A, Grosskurth H, Newell J, Todd J, et al. A community trial of the impact of improved sexually transmitted disease treatment on HIV epidemic in rural Tanzania. 1. Design. AIDS 1995;9:919-26.
8. Wawer MJ, Sewankambo NK, Serwadda, D, et al. Control of sexually transmitted disease for AIDS prevention in Uganda: A randomized community trial. Lancet 1999;353:525-35.
9. Hayes R.J., Alexander N.D.E., Bennett S., Cousens S.N., Design and analysis issues in cluster-randomized trials of interventions against infectious diseases. Stat Methods in Med Res. 9:2000;95-116.
10. Koepsell TD, Wagner EH, Cheadle AC, Patrick DL, Martin DC, Diehr PH, et al. Selected methodological issues in evaluating community-based health promotion and disease prevention programs. Ann. Rev. Public Health 1992;13:31-57.
11. Donner A., Some aspects of the design and analysis of cluster randomization trials. Appl. Stat. 47:1998;95-114.
12. Prentice R., Sheppard L., Aggregate data studies of disease risk factors. Biometrika. 82:1995;113-125.
13. Klar N., Gyorkos T., Donner A., Cluster randomization trials in tropical medicine: a case study. Trans R Soc Trop Med Hyg. 89:1995;454-459.
14. Murray DM. Design and Analysis of Group-Randomized Trials. New York: Oxford University Press, 1998.
15. Kermack W.O., McKendrick A.G., A contribution to the mathematical theory of epidemics. Proc R Soc London Ser A. 115:1927;700-721.
16. Whittle P., The outcome of a stochastic epidemic - a note on Bailey's paper. Biometrika. 42:1955;116-122.
17. Bailey NTJ. The Mathematical Theory of Epidemics. London: Griffin, 1957.
18. Becker NG. Analysis of Infectious Disease Data. London: Chapman & Hall, 1989.
19. Anderson RM, May RM. Infectious Diseases of Human: Dynamics and Control. Oxford: Oxford University Press, 1991.
20. Elveback L.R., Fox J.P., Ackerman E., Langworthy A., Boyd M., Gatewood L., An influenza simulation model for immunization studies. Am J Epidemiol. 103:1976;152-165.
21. Longini I.M., Ackerman E., Elveback L.R., An optimization model for influenza A epidemics. Math Biosci. 38:1978;141-157.
22. Longini IM. Modeling influenza epidemics. In: Kendal AP, Patriarca PA, editors. Proceedings of the UCLA Symposia on Molecular and Cellular Biology, Options for the control of influenza, New Series, vol. 36. New York: Alan Liss, 1986. p. 89-105.
23. Poland G.A., Hall C.B., Influenza immunization of schoolchildren: can we interrupt community epidemics? Pediatrics. 103:1999;1280-1281.
24. Piedra PA, Gaglani M, Herschler G, Kozinetz C, Glezen WP. Safety and effectiveness of the trivalent, cold-adapted influenza virus (CAIV-T) vaccine in a community-based, non-randomized, open-label trial in children. Pediatr Res 47, 2000 [abstract].
25. Longini I.M., Halloran M.E., Haber M.J., Chen R.T., Measuring vaccine efficacy from epidemics of acute infectious agents. Stat Med. 12:1993;249-263.
26. Ball F., Clancy D., The final size and severity of a generalised stochastic multitype epidemic model. Adv Appl Probability. 25:1993;721-736.
27. Longini I.M., Halloran M.E., Nizam A., Model-based estimation of vaccine effects from community vaccine trials. Stat Med. 21:2002;481-496.
28. Lin Z., An issue of statistical analysis in controlled multi-centre studies: how shall we weight the centres? Stat Med. 18:1999;365-373.
29. United States Census Bureau. Census 2000, retrieved 25 July 2001 [ http://www.census.gov/ ].
30. Smith P.G., Rodrigues L.C., Fine P.E.M., Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol. 13(1):1984;87-93.
31. Halloran M.E., Haber M.J., Longini I.M., Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol. 136:1992;328-343.
32. Fine P.E., Zell E.R., Outbreaks in highly vaccinated populations: implications for studies of vaccine performance. Am J Epidemiol. 139:1994;77-90.
33. Halloran M.E., Struchiner C.J., Causal inference for infectious diseases. Epidemiology. 6:1995;142-151.
34. Longini IM, Halloran ME, Nizam A, Wolff M, Mendelman PM, Fast P, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 2000;18:1902-9.
35. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000;136:168-175.
36. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. J Inf Dis 2000;181:1133-7.
37. University of Minnesota National Micropopulation Simulation Resource. Simex Simulation Resource. World Wide Web/Internet, December 1998 [http://www.labmed.umn.edu/nmsr/simex].
38. Longini I.M., Koopman J.S., Haber M., Cotsonis G.A., Statistical inference for infectious diseases: risk-specified household and community transmission parameters. Am J Epidemiol. 128(4):1988;845-859.
39. Addy C.L., Longini I.M., Haber M.S., A generalized stochastic model for the analysis of infectious disease final size data. Biometrics. 47:1991;961-974.